Journal decision profile

Research in Pharmaceutical Sciences

Medicine · Biochemistry, Genetics and Molecular Biology

Research in Pharmaceutical Sciences' 2026 Journal Metrics Score is 2.2, ranking Q2 in Organic Chemistry and 2 other subfields. Two-year citation average from OpenAlex data, updated August 2026.

MedknowIRpISSN 1735-5362eISSN 1735-9414
Checking system sharing availability.Visit homepage

Bookmark this page — track observed submission-to-acceptance timing, FWCI and field-normalized citation data for this journal in one view.

Journal Metrics Score
i
Journal Metrics ScoreThe raw score is citations received in the latest complete year by works from the two previous years, divided by the number of those works. It is calculated from OpenAlex open data (CC0) and is not a percentage grade.
2026
2.2

Journal Metrics Score 2026 · 2021–2024 window citedness 2.40.

Review & acceptance time
i
Review & acceptance timeCalendar days between the received and accepted dates reported in recent PubMed records. This interval includes editorial handling and author revisions, so it is not time to first decision or pure peer-review time.
PUBMED
169 daysmedian

Middle 50%: 114–308 days

99 of 100 PubMed-indexed articles · 99% coverage · 2024–2025

Research in Pharmaceutical Sciences accepts papers a median of 169 days after submission, including peer review and revisions. That is slower than 91% of comparable journals with PubMed timing data.

Indicative APC
i
Indicative APCThis journal-level estimate comes from the OpenAlex source record. It is not a verified quote and may exclude taxes, waivers, society discounts, or article-type charges. Check the journal's official website before deciding.
OPENALEX · VERIFY
$500

Journal-level estimate only. Verify current charges, taxes, waivers, discounts, and article-type fees with the journal.

Free preview · no sign-in

Does your manuscript fit Research in Pharmaceutical Sciences?

Paste your title to see which of this journal's published topics it overlaps with. Your title stays in your browser for this preview and is not sent anywhere.

Want ranked journals with fit reasons, risks and a submission strategy instead? See a sample AI report.

At a glance

Journal decision profile

Each spoke is a 0–100 percentile within a comparable journal cohort—not a percentage grade or a single black-box rating.

Relative profile

Metrics ScoreThe raw 2026 Journal Metrics Score is the recent two-year citation average shown above. The radar converts it to a 0–100 cohort percentile: farther out means a higher score than more comparable journals. It is not a percentage grade.iSource outputThe raw rank compares lifetime output inside the journal’s leading-topic source set. The radar then compares that rank position across Decision Profile journals in the same primary OpenAlex field; when that field has too few profiles, it uses the broader profile set. Farther out means relatively more output, not better research quality.iTop 10% shareThe share of recent papers in the global top 10% for citations after comparing papers of the same type, publication year, and subfield. The radar converts that share to a 0–100 cohort percentile; it does not predict how a new paper will perform.iMedian FWCICitation performance of the middle recent paper after field, year, and work type are considered. A raw FWCI of 1.0 is the expected citation level for comparable papers; the radar shows its 0–100 cohort percentile.iSubmission-to-acceptanceCalendar days from the received date to the accepted date in recent PubMed records. This includes editorial handling and author revisions, so it is not the time to first decision and not pure peer-review time. The radar uses a 0–100 cohort percentile with shorter observed timing plotted farther out; it does not measure review quality.iOutput volumeAverage works published per year in the recent analysis window, converted to a 0–100 cohort percentile. Farther out means the journal publishes more papers; it does not mean those papers are better.i
Cost is intentionally excluded. Missing APC data is never converted to a zero-dollar fee or a fabricated cost score.

Raw values behind the shape

Always visible
Metrics Score
i
Metrics ScoreThe 2026 raw Journal Metrics Score shown above. The bar is its 0–100 percentile within the radar's comparable journal cohort; it is not a percentage score.
2.22026 · OPENALEX
Source output rank
i
Source output rankThis lifetime journal-wide output rank compares works published by the OpenAlex source with sources associated with the journal’s leading topic. More output does not mean higher quality.
#293 / 2,239LIFETIME OUTPUT
Highly cited papers
i
Highly cited papersShare of recent works in the global top 10% for citations after comparing papers of the same type, publication year, and subfield.
3.4%FIELD-NORMALIZED TOP 10%
Field-normalized impact
i
Field-normalized impactCitation performance of the middle recent paper after field, year, and work type are considered. A raw FWCI of 1.0 is the expected level for comparable work.
0.78MEDIAN FWCI
Submission-to-acceptance
i
Submission-to-acceptanceReceived-to-accepted calendar days from qualified PubMed records. It includes editorial handling and author revisions; it is not time to first decision or pure peer-review time.
169 daysIQR 114–308 DAYS
Recent output
i
Recent outputAverage works published per year across the complete analysis window. This is a volume measure, not a quality score.
58 / yr2021–2024 AVG
Field-normalized top 10% share3.4%

8 of 232 works · same type, year & subfield

Field-normalized top 1% share0%

0 works · same type, year & subfield

Median FWCI0.78×

Below field-year expectation

Source output rank#293

of 2,239 topic-associated OpenAlex sources by lifetime output

What does Median FWCI mean?

FWCI compares papers with the same publication year, type, and field. 1.0 is the world average; above 1.0 is above expectation. This journal's median is 0.78, so its typical recent paper runs about 22% below its field benchmark.

What does Top 10% Share mean?

3.4% of recent papers rank in the global top 10% after field normalization. This is easier to compare across specialties than raw citation totals.

Publishing pattern

Publication volume and article mix

Volume is separated from citation accumulation so newer papers are not presented as weaker simply because they are newer.

Works published by year

OpenAlex source records · 2016–2025

312016
712017
502018
612019
702020
602021
612022
512023
602024
702025

Recent work-type mix

232 OpenAlex works · 2021–2024

Article98.3%
Review1.7%
OpenAlex article is broader than “original research.” PubMed Publication Types can add case-report and clinical-study detail.
Fit signals

Topics and research coverage

OpenAlex topics show the research communities this journal serves.

Leading OpenAlex topics

2021–2024 works
Computational Drug Discovery Methods13
Medicinal Plant Research10
Chemotherapy-induced organ toxicity mitigation8
Curcumin's Biomedical Applications6
Pain Mechanisms and Treatments6
Drug-Induced Hepatotoxicity and Protection5
Medicinal Plants and Neuroprotection5
Natural Antidiabetic Agents Studies5
Synthesis and biological activity5
Drug Solubulity and Delivery Systems4
Methodology: OpenAlex snapshot 2026-10-16. FWCI, percentile badges, topics, and type mix use 232 works published 2021–2024. Radar normalization is versioned in the cached profile, and no cost score is assigned without reliable APC data.

Subject Category Quartiles

Quartiles computed within each OpenAlex subfield
CategoryQuartile
Organic ChemistryQ2
Pharmaceutical ScienceQ3
Plant ScienceQ2
Food ScienceQ2

Is Research in Pharmaceutical Sciences a good journal?

A solid Q2 journal by citation data

By citation data, Research in Pharmaceutical Sciences is a solid journal: it is Q2 in Organic Chemistry and 2 other subfields, the second quarter of journals by score, and ranks #1,779 of 3,784 Biology & Basic Science journals by Journal Metrics Score (top 48%). Research in Pharmaceutical Sciences' 2026 Journal Metrics Score is 2.2. Recent papers took a median of 169 days from submission to acceptance, according to PubMed dates. OpenAlex lists an indicative article processing charge of $500 USD. OpenAlex classifies its papers in subfields including Organic Chemistry, Pharmaceutical Science, and Plant Science, so check that your topic fits its scope.

Best quartile
Q2
Organic Chemistry
Rank in Biology & Basic Science
#1,779 of 3,784
Top 48%
2026 Journal Metrics Score
2.2
Acceptance rate
Not published
By the journal or publisher
Submission to acceptance
169 days
Median, PubMed records
Open access fee (APC)
$500
OpenAlex, verify with the journal
Papers published in 2025
70
OpenAlex works

Check before you submit

  • Confirm the current article processing charge, waivers, and any institutional agreement on the journal website; the OpenAlex figure is indicative.
  • Confirm the journal is indexed where your institution or funder requires (for example Scopus or PubMed) before you submit.

Verdict from citation data only: quartile and field rank by Journal Metrics Score (OpenAlex), publisher-reported acceptance rates, and PubMed submission and acceptance dates. See how we rank journals and how to verify indexing.

Q2
Subfield Quartile
N/A
CAS Block

Ranking and source check

#1,779
of 3,784 Biology & Basic Science field journals
#387
among Q2 Biology & Basic Science journals

Confirm the exact title and ISSNs against the publisher homepage before a high-stakes submission decision.

Journal Details

OpenAlex Works
1,605
H-Index
36
Fully Open Access
Yes
Recent OA Works
622
Subject Areas
Organic ChemistryPharmaceutical SciencePlant ScienceFood Science

Source: the current OpenAlex source record. OpenAlex works can include multiple work types. Fully Open Access is a source-level flag. Recent OA Works is summed from OpenAlex's counts_by_year series (up to the latest ten years); it is not a lifetime OA percentage. Any APC shown here is an indicative OpenAlex value—verify current charges on the journal's official website.

How to submit to Research in Pharmaceutical Sciences

  1. 1

    Check the scope

    OpenAlex classifies Research in Pharmaceutical Sciences' papers in subfields including Organic Chemistry, Pharmaceutical Science, and Plant Science. Read the aims and scope page and a few recent papers close to your topic before you prepare the manuscript.

  2. 2

    Follow the author guidelines

    Article types, word and figure limits, reference style, and the required statements (data availability, ethics, conflicts of interest, author contributions) are set by the journal. Prepare the cover letter and files to match them.

    Research in Pharmaceutical Sciences homepage ↗
  3. 3

    Submit online

    Use the submit link in Research in Pharmaceutical Sciences' author guidelines; Medknow runs the submission site. Every author usually needs an ORCID iD, and the corresponding author needs an account on the submission site.

  4. 4

    Plan for costs

    OpenAlex lists an indicative article processing charge of $500 USD for this open-access journal. Check the current fee, waivers, and any institutional agreement on the journal website.

  5. 5

    Know what to expect

    Recent accepted papers took a median of 169 days from submission to acceptance, including revisions (PubMed dates). Research in Pharmaceutical Sciences does not publish an acceptance rate.

Reviewer Two · coming soon

Know what reviewers will say before you submit to Research in Pharmaceutical Sciences

An AI pre-submission report on your manuscript: the objections a tough reviewer is likely to raise, desk-rejection risks, and better-fit journals from our data. $29 per report.

See what the report covers

Common questions about Research in Pharmaceutical Sciences

Is Research in Pharmaceutical Sciences a good journal?

By citation data, Research in Pharmaceutical Sciences is a solid journal: it is Q2 in Organic Chemistry and 2 other subfields, the second quarter of journals by score, and ranks #1,779 of 3,784 Biology & Basic Science journals by Journal Metrics Score (top 48%). Research in Pharmaceutical Sciences' 2026 Journal Metrics Score is 2.2. Recent papers took a median of 169 days from submission to acceptance, according to PubMed dates. OpenAlex lists an indicative article processing charge of $500 USD. OpenAlex classifies its papers in subfields including Organic Chemistry, Pharmaceutical Science, and Plant Science, so check that your topic fits its scope.

What is Research in Pharmaceutical Sciences' Journal Metrics Score in 2026?

Research in Pharmaceutical Sciences' 2026 Journal Metrics Score is 2.2, from the August 2026 data release. The score is a two-year citation average computed from OpenAlex (CC0) data: citations received in the most recent complete year to works published in the two prior years, divided by the number of those works.

What is the acceptance rate of Research in Pharmaceutical Sciences?

We have not found an official acceptance rate published by Research in Pharmaceutical Sciences or its publisher, and Journal Metrics does not estimate one because submission counts are not public. What recent PubMed records do show is speed: accepted papers took a median of 169 days from submission to acceptance. To judge selectivity, compare Research in Pharmaceutical Sciences' quartile and score with similar journals, or ask the editorial office.

What quartile is Research in Pharmaceutical Sciences in?

Research in Pharmaceutical Sciences' best quartile is Q2. By OpenAlex subfield: Q2 in Organic Chemistry; Q3 in Pharmaceutical Science; Q2 in Plant Science; Q2 in Food Science. Quartiles rank journals by Journal Metrics Score within each subfield.

Is the Journal Metrics Score the same as other journal citation metrics?

No. Journal Metrics computes the score independently from OpenAlex open data. Other providers use different citation databases, document types, and counting rules, so their published figures for Research in Pharmaceutical Sciences will not match this score exactly. Compare journals using one source at a time.

How long does Research in Pharmaceutical Sciences take to accept a paper?

Research in Pharmaceutical Sciences accepts papers a median of 169 days after submission across 99 recent PubMed records with both dates; the middle half took 114–308 days. This includes peer review, editorial handling, and revisions.

How long is the peer review time at Research in Pharmaceutical Sciences?

PubMed records when a manuscript was received and accepted, not the individual review stages, so peer review time on its own is not available. The full time from submission to acceptance at Research in Pharmaceutical Sciences, which includes peer review and revisions, has a median of 169 days. For the time to a first decision, check the journal's own website.

Is Research in Pharmaceutical Sciences faster than similar journals?

Research in Pharmaceutical Sciences' median of 169 days from submission to acceptance is slower than 91% of comparable journals with PubMed timing data.

How much does it cost to publish in Research in Pharmaceutical Sciences?

OpenAlex lists an indicative article processing charge of $500 USD for Research in Pharmaceutical Sciences. This journal-level estimate may exclude taxes, waivers, discounts, or article-type fees, so confirm the current charge on the journal's website.

Which journals are alternatives to Research in Pharmaceutical Sciences?

Comparable journals include Journal of Pharmacy & Pharmacognosy Research, Beni-Suef University Journal of Basic and Applied Sciences, Advances in Pharmacological and Pharmaceutical Sciences, and Current Topics in Medicinal Chemistry. Compare their scores, acceptance times, and costs in the recommended alternatives on this page before choosing where to submit.

How do I submit a paper to Research in Pharmaceutical Sciences?

Submit online through the link in Research in Pharmaceutical Sciences' author guidelines on the journal homepage. Before submitting, check the scope, follow the author guidelines for article type, length, and required statements, and prepare a cover letter. Accepted papers took a median of 169 days from submission to acceptance in recent PubMed records.

Cite an article from this journal
Back to Search